Engineered growth factors and cutaneous wound healing: Success and possible questions in the past 10 years

• Published in: Wound repair and regeneration 2005-03, Vol.13 (2), p.122-130
• Main Authors: Fu, Xiaobing, Li, Xiaokun, Cheng, Biao, Chen, Wei, Sheng, Zhiyong
• Format: Article
• Language: English
• Subjects: Drug Delivery Systems; Growth Substances - pharmacology; Humans; Professional Practice; Recombinant Proteins; Skin - drug effects; Time Factors; Wound Healing - drug effects
• ISSN: 1067-1927; 1524-475X
• DOI: 10.1111/j.1067-1927.2005.130202.x

In the past 10 years, many engineered growth factors, including recombinant human epidermal growth factor, basic fibroblast growth factor, and platelet‐derived growth factor, have been produced and used in the clinic. After screening the results from different centers, some results are found to be encouraging, while others are discouraging. Although the interpretation of these results may depend on your perspective, it may also depend on different criteria, different wounds, and even different aims. In this article, successful experiences and failures concerning the use of growth factors and cutaneous wound healing are summarized. Based on this information and our clinical experience, we address people's concerns such as whether growth factors have altered clinical practice thus far and whether growth factor treatments have solved all problems involved in wound healing. Is there a need for exogenous application of growth factors in acute or chronic wounds, and if so, is it safe to use growth factors to promote wound healing? Last, can we achieve perfect wound healing in those wounds treated with growth factors?